Health Canada Registered
Hybrid XL Products (Instrument Only)
News and Updates
DRG is proud to announce the launch of two new Anti-Müllerian Hormone (AMH) assays: AMH ELISA (EIA-6141) AMH DRG HYBRiD XL® (HYE-5770) Clinical Application: AMH has been identified as a reliable marker of ovarian reserve that can help predict early ovarian...
The growth and further development of the North American market is a key priority for us and the sole focus of the new Sales and Business Development Executive we are looking to recruit.
On April 30th, 2020, an organized study by Radboud University Medical Center in Nijmegen, Netherlands, has completed a final report for the DRG International’s first ever Hepcidin Proficiency Test.